[1] Aljumah AA, Al-Ashgar H, Fallatah H, et al. Acute onset autoimmune hepatitis: clinical presentation and treatment outcomes. Ann Hepatol, 2019, 18(3): 439-444. [2] Shen Y, Lu C, Men R, et al. Clinical and pathological characteristics of autoimmune hepatitis with acute presentation. Can J Gastroenterol Hepatol, 2018, 2018: 3513206. [3] Joshita S, Yoshizawa K, Umemura T, et al. Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey. J Gastroenterol, 2018, 53(9): 1079-1088. [4] Pacurar D, Dijmarescu I, Dijmarescu A, et al. Autoimmune phenomena in treated and naive pediatric patients with chronic viral hepatitis. Exp Ther Med, 2019, 18(6): 5101-5104. [5] Muratori P. Comment on "clinical and pathological characteristics of autoimmune hepatitis with acute presentation". Can J Gastroenterol Hepatol, 2020, 2020: 3895375. [6] Fujiwara K, Yokosuka O, Kato N. Histological re-evaluation of autoimmune hepatitis with acute presentation. Liver Int, 2022, 42(8): 1916-1917. [7] Urzua A, Pizarro C, Gajardo A, et al. Autoimmune hepatitis with acute presentation: clinical, biochemical, and histological features of 126 patients. Can J Gastroenterol Hepatol, 2022, 2022: 6470847. [8] Perera Mesa H, Lugo L, Altshuler E. Hepatocellular carcinoma in patients with liver cirrhosis secondary to autoimmune hepatitis: a case series and literature review. Cureus, 2022, 14(10): e30698. [9] Que W, Lin H, Li X, et al. Koumine ameliorates concanavalin a-induced autoimmune hepatitis in mice: involvement of the nrf2, nf-kappab pathways, and gut microbiota. Int Immunopharmacol, 2023, 114: 109573. [10] Zarachi A, Pelechas E, Tsikou A, et al. Immune-mediated inner ear disease associated with type 1 autoimmune hepatitis: a challenging coexistence. Mediterr J Rheumatol, 2022, 33(3): 349-360. [11] Mungmunpuntipantip R, Wiwanitkit V. Autoimmune hepatitis triggered by covid-19 vaccination: correspondence. Clin J Gastroenterol, 2022, 15(5): 1026. [12] Fan X, Shen Y, Yang F, et al. Factors and cytokine signatures associated with the response to therapy in patients with primary biliary cholangitis-autoimmune hepatitis overlap syndrome: a real-world study. Chin Med J (Engl),2023,136(6):735-736. [13] Sirbe C, Simu G, Szabo I, et al. Pathogenesis of autoimmune hepatitis-cellular and molecular mechanisms. Int J Mol Sci, 2021, 22(24):1212-1217. [14] Ramonet M, Ramirez-Rodriguez N, Alvarez Chavez F, et al. Autoimmune hepatitis in pediatrics, a review by the working group of the Latin American society for pediatric gastroenterology, hepatology, and nutrition. Arch Argent Pediatr, 2022, 120(4): 281-287. [15] Olivas I, Cobreros M, Londono MC, et al. Budesonide in the first line treatment of patients with autoimmune hepatitis. Gastroenterol Hepatol, 2022, 45(7): 561-570. [16] Harrington CR, Levitsky J. Alloimmune versus autoimmune hepatitis following liver transplantation. Clin Liver Dis (Hoboken), 2022, 20(1): 21-24. [17] Sucher E, Sucher R, Gradistanac T, et al.Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res, 2019, 2019: 9437043. [18] Snijders RJ, Milkiewicz P, Schramm C, et al.Health-related quality of life in autoimmune hepatitis. World J Hepatol, 2021, 13(11): 1642-1652. [19] Czaja AJ. Examining pathogenic concepts of autoimmune hepatitis for cues to future investigations and interventions. World J Gastroenterol, 2019, 25(45): 6579-6606. [20] Mataya L, Patel N, Azzam RK. Autoimmune liver diseases in children. Pediatr Ann, 2018, 47(11):e452-e457. |